| Chlorella (Chlorella vulgaris) — a unicellular freshwater green microalga consumed as dried whole biomass, tablets, powders, or extracts. It is best classified as a food source / microalgal nutraceutical rather than as a single pharmacologically defined compound. Chlorella biomass contains protein, chlorophylls, carotenoids including lutein and β-carotene, polyunsaturated fatty acids, vitamins, minerals, phenolic compounds, and polysaccharides; composition varies substantially with strain, cultivation, processing, and extraction. “Chlorella growth factor” or CGF refers to water-soluble Chlorella-derived material rather than a single defined molecule. Chlorella is marketed as a food/dietary supplement and has no established or approved indication for cancer treatment.
Primary mechanisms (ranked):
- Induction of intrinsic and extrinsic apoptotic signaling in susceptible cancer models, including ↑ p53/Bax/caspase activity and ↓ Bcl-2.
- Suppression of prosurvival AKT/mTOR signaling by some Chlorella extracts, reducing proliferation and promoting apoptosis.
- ROS-mediated oxidative stress and mitochondrial dysfunction in cancer cells at sufficiently high extract concentrations; this is strongly preparation- and dose-dependent.
- DNA damage and associated cell-death signaling reported with hot-water and other extracts in several cancer cell models.
- Immunomodulation, including enhanced natural-killer-cell activity and other immune-response markers in humans; direct anticancer relevance remains unproven.
- Antioxidant and anti-inflammatory effects in non-cancer settings, potentially mediated by carotenoids, chlorophyll derivatives, phenolics, polysaccharides, and improved endogenous antioxidant defenses.
- Possible antiangiogenic and antitumor effects observed in animal models, but evidence is limited and may not generalize across Chlorella species or preparations.
Bioavailability / PK relevance: Chlorella is a complex food matrix rather than a single PK-defined agent. Oral absorption is constituent-specific. Human kinetic studies demonstrate systemic absorption of lutein, β-carotene, zeaxanthin and some lipid/micronutrient components after ingestion, but intact-cell walls can substantially restrict pigment bioaccessibility. Cell disruption, sonication, milling, extraction, emulsification, and co-ingestion with dietary fat can materially alter bioavailability. There is no meaningful single plasma half-life, Cmax, or systemic exposure value for “Chlorella” as a whole.
In-vitro vs systemic exposure relevance: Many reported anticancer experiments use Chlorella extracts at approximately hundreds of µg/mL to several mg/mL. These concentrations represent direct exposure to crude extracts and cannot be assumed achievable in human tumors after oral consumption of whole Chlorella. Consequently, apoptosis, AKT/mTOR inhibition, ROS generation, and DNA-damage findings should be interpreted as preclinical extract effects rather than demonstrated systemic effects of dietary Chlorella.
Clinical evidence status: Preclinical for cancer treatment. Anticancer evidence consists predominantly of cell-culture studies and limited animal experiments; there is no established randomized clinical evidence demonstrating tumor regression, improved cancer survival, or efficacy as an oncology adjunct. Human randomized studies have evaluated immune, antioxidant, lipid, metabolic, blood-pressure, and other physiological endpoints rather than cancer treatment. Oral Chlorella is generally tolerated in studied populations, but gastrointestinal effects and rare allergic or photosensitivity reactions can occur. Its relatively high vitamin K content can antagonize warfarin, making anticoagulant interaction an important clinical constraint.
Chlorella Mechanistic Profile
| Rank |
Pathway / Axis |
Cancer Cells |
Normal Cells |
TSF |
Primary Effect |
Notes / Interpretation |
| 1 |
Apoptosis and Bcl-2 family signaling |
↑ p53, ↑ Bax, ↑ caspase-3/7/8/9, ↓ Bcl-2 |
Generally less cytotoxic in some comparative models |
G |
Apoptotic cell death |
Among the most consistently reported anticancer effects of Chlorella-derived extracts; magnitude depends strongly on extract type, concentration, and cell line. |
| 2 |
AKT mTOR survival signaling |
↓ p-AKT, ↓ p-mTOR |
↔ or ↑ PI3K AKT signaling reported in some normal-cell models |
R/G |
Reduced survival signaling and proliferation |
Demonstrated particularly with ethanolic Chlorella extracts in cholangiocarcinoma models; not established as a systemic effect after oral whole-biomass supplementation. |
| 3 |
Mitochondria and membrane potential |
↓ mitochondrial membrane potential |
Limited evidence |
R/G |
Intrinsic apoptotic signaling |
Reported in breast-cancer and related experimental models and commonly accompanies ROS elevation and caspase activation. |
| 4 |
ROS and oxidative stress |
↑ ROS (dose-dependent) |
↓ systemic oxidative-stress markers in some human supplementation studies; ↑ ROS and reversible DNA damage possible with concentrated cellular exposure |
R |
Oxidative stress and damage in cancer models |
Bidirectional and context-dependent. Chlorella can behave as an antioxidant nutritionally while concentrated extracts may produce pro-oxidant effects in cultured cells. |
| 5 |
DNA damage response |
↑ DNA damage, ↑ γH2AX or comet-assay damage in selected models |
↑ reversible DNA damage at sufficiently high direct exposure in some epithelial models |
R/G |
Genotoxic stress preceding cell death |
Not cancer-selective in all experiments. This prevents interpreting DNA damage itself as an inherently therapeutic mechanism. |
| 6 |
Immune and natural killer cell activity |
Indirect |
↑ NK-cell activity and selected cytokine responses |
G |
Immune modulation |
Supported by a small randomized human trial in healthy subjects. Whether this produces clinically meaningful antitumor immunity in cancer patients is unknown. |
| 7 |
Angiogenesis |
↓ VEGFR2 or angiogenic signaling (model-dependent) |
Insufficient evidence |
G |
Potential suppression of tumor vascular support |
Evidence is mainly from experimental animal work using Chlorella pyrenoidosa and should not automatically be generalized quantitatively to C. vulgaris. |
| 8 |
Antioxidant defense |
Context-dependent |
↑ antioxidant micronutrient status, ↑ endogenous antioxidant defenses, ↓ lipid peroxidation in some studies |
G |
Reduction of systemic oxidative stress |
Likely reflects multiple constituents including carotenoids and other micronutrients rather than one Chlorella-specific molecular target. |
| 9 |
Clinical Translation Constraint |
In-vitro active concentrations frequently high |
Oral supplementation generally tolerated; vitamin K interaction is clinically important |
G |
Limits translation of laboratory anticancer findings |
Crude extracts at hundreds of µg/mL to mg/mL cannot be equated with concentrations achievable after oral ingestion. Cell-wall disruption and formulation strongly affect constituent bioaccessibility. No demonstrated clinical anticancer efficacy. |
P: 0–30 min R: 30 min–3 hr G: >3 hr
|